Testicular Cancer: Epidemiology, Diagnosis, and Management

Zachary L Smith; Ryan P Werntz; Scott E Eggener

doi:10.1016/j.mcna.2017.10.003

Testicular Cancer: Epidemiology, Diagnosis, and Management

Med Clin North Am. 2018 Mar;102(2):251-264. doi: 10.1016/j.mcna.2017.10.003. Epub 2017 Dec 21.

Authors

Zachary L Smith¹, Ryan P Werntz², Scott E Eggener²

Affiliations

¹ Section of Urology, Department of Surgery, The University of Chicago Medicine, 5841 South Maryland Avenue, MC 6038, Chicago, IL 60637, USA. Electronic address: zachary.smith@uchospitals.edu.
² Section of Urology, Department of Surgery, The University of Chicago Medicine, 5841 South Maryland Avenue, MC 6038, Chicago, IL 60637, USA.

PMID: 29406056
DOI: 10.1016/j.mcna.2017.10.003

Abstract

There were an estimated 8720 new cases of testicular cancer (TC) in the United States in 2016. The cause of the disease is complex, with several environmental and genetic risk factors. Although rare, the incidence has been steadily increasing. Fortunately, substantial advances in treatment have occurred over the last few decades, making TC one of the most curable malignancies. However, because TC typically occurs in younger men, considerations of the treatment impact on fertility, quality of life, and long-term toxicity are paramount; an individualized approach must be taken with patients based on their clinical and pathologic findings.

Keywords: Chemotherapy; Germ cell tumors; Nonseminoma; Orchiectomy; Radiation therapy; Retroperitoneal lymph node dissection; Seminoma; Testicular cancer.

Publication types

Review

MeSH terms

Humans
Male
Testicular Neoplasms / diagnosis*
Testicular Neoplasms / epidemiology
Testicular Neoplasms / mortality
Testicular Neoplasms / therapy*